| 发明名称 |
HCV Combination Therapy |
| 摘要 |
The present invention relates to the treatment of hepatitis C (HCV) infection by the combination treatment with a miR-122 inhibitor and a HCV NS5A RNA protein inhibitor. |
| 申请公布号 |
US2014213632(A1) |
申请公布日期 |
2014.07.31 |
| 申请号 |
US201214128508 |
申请日期 |
2012.06.25 |
| 申请人 |
Hodges Michael |
发明人 |
Hodges Michael |
| 分类号 |
A61K31/713;A61K31/4178;A61K31/7056 |
主分类号 |
A61K31/713 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A miR-122 inhibitor for use in the treatment of Hepatitis C (HCV) in combination with an HCV NS5A RNA protein inhibitor, and/or optionally ribavirin (or a virally active derivative thereof). |
| 地址 |
San Diego CA US |
